ZA201706612B - Fused bicyclic heteroaryl derivatives having activity as phd inhibitors - Google Patents

Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Info

Publication number
ZA201706612B
ZA201706612B ZA2017/06612A ZA201706612A ZA201706612B ZA 201706612 B ZA201706612 B ZA 201706612B ZA 2017/06612 A ZA2017/06612 A ZA 2017/06612A ZA 201706612 A ZA201706612 A ZA 201706612A ZA 201706612 B ZA201706612 B ZA 201706612B
Authority
ZA
South Africa
Prior art keywords
activity
bicyclic heteroaryl
fused bicyclic
heteroaryl derivatives
phd inhibitors
Prior art date
Application number
ZA2017/06612A
Other languages
English (en)
Inventor
Ahmed Saleh
Barker Gregory
Canning Hannah
Davenport Richard
Harrison David
Jenkins Kerry
Livermore David
Wright Susanne
Kinsella Natasha
Original Assignee
Takeda Pharmaceutical Company Ltd A Japanese Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Ltd A Japanese Company filed Critical Takeda Pharmaceutical Company Ltd A Japanese Company
Publication of ZA201706612B publication Critical patent/ZA201706612B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2017/06612A 2015-03-18 2017-10-02 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors ZA201706612B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (1)

Publication Number Publication Date
ZA201706612B true ZA201706612B (en) 2019-01-30

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/06612A ZA201706612B (en) 2015-03-18 2017-10-02 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (1) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049305T2 (hu) 2016-02-24 2020-09-28 Pfizer Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok
US11254668B2 (en) 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
ES3016010T3 (en) * 2018-09-13 2025-05-08 Kissei Pharmaceutical Imidazopyridinone compound
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
EP4122928A4 (en) * 2020-04-20 2023-12-13 Shenzhen TargetRx, Inc. SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE AND PRODUCTION AND USE THEREOF
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
JP2024541910A (ja) 2021-10-28 2024-11-13 インシリコ メディシン アイピー リミテッド プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
PL360027A1 (en) 2000-06-30 2004-09-06 Wyeth Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
HRP20140705T1 (hr) * 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
JPWO2014030716A1 (ja) * 2012-08-23 2016-08-08 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
ES2774052T3 (es) 2020-07-16
PH12017501699B1 (en) 2023-06-30
EP3271357A1 (en) 2018-01-24
UA123668C2 (uk) 2021-05-12
CA2979024C (en) 2024-02-20
ECSP17069696A (es) 2018-02-28
EA035739B1 (ru) 2020-08-03
PT3271357T (pt) 2020-02-21
EP3271357B1 (en) 2019-11-27
KR20170129874A (ko) 2017-11-27
JP6726681B2 (ja) 2020-07-22
KR102609431B1 (ko) 2023-12-04
DK3271357T3 (da) 2020-02-17
CN107531698B (zh) 2024-08-13
MX2017011902A (es) 2017-12-15
AU2016234209A1 (en) 2017-10-12
BR112017019653A2 (pt) 2018-05-15
WO2016148306A1 (en) 2016-09-22
NZ735631A (en) 2023-07-28
MY194873A (en) 2022-12-21
HUE047918T2 (hu) 2020-05-28
CL2017002354A1 (es) 2018-05-04
IL254277A0 (en) 2017-10-31
GB201504565D0 (en) 2015-05-06
CN107531698A (zh) 2018-01-02
HK1249512A1 (en) 2018-11-02
DOP2017000209A (es) 2017-10-15
AU2016234209B2 (en) 2020-08-27
EA201792057A1 (ru) 2018-04-30
PE20180656A1 (es) 2018-04-17
PH12017501699A1 (en) 2018-03-12
JP2018512408A (ja) 2018-05-17
US10287286B2 (en) 2019-05-14
CR20170468A (es) 2018-04-27
IL254277B (en) 2020-10-29
CO2017009353A2 (es) 2017-11-30
BR112017019653B1 (pt) 2023-10-03
SG11201707280VA (en) 2017-10-30
US20180072714A1 (en) 2018-03-15
CA2979024A1 (en) 2016-09-22
GEP20207095B (en) 2020-04-10
TN2017000384A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
ZA201706612B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
IL256808A (en) Heteroaryl derivatives as parp inhibitors
IL246140B (en) History of bicyclic heterocyclics as bromodomain repressors
ZA201801032B (en) Bicyclic compounds as atx inhibitors
IL253691B (en) Bicyclic heterocyclics as fgfr inhibitors
IL253869B (en) Bicyclic heterocyclics as fgfr4 inhibitors
ZA201800480B (en) New bicyclic compounds as dual atx/ca inhibitors
IL255570A (en) Bicyclic compounds as atx inhibitors
SMT202200250T1 (it) Composti eterociclici come inibitori della pi3k-gamma
SG11201706729SA (en) Derivatives of sobetirome
IL253588B (en) History of bicyclic quinazolinones
IL255511B (en) New bicyclic compounds as dual atx/ca inhibitors
EP3323809A4 (en) Bicyclic heterocyclic amide derivative
IL255357A0 (en) bicyclic compounds
EP3275874A4 (en) Fused heterocyclic compound
ZA201706038B (en) Bicyclic pyridine compound